Foxo1-Rictor axis mediates adaptive increase in Akt activity and cell survival during BCR inhibitor therapy in chronic lymphocytic leukemia.

Investor logo
Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.
Authors

HLAVÁČ Kryštof ONDRIŠOVÁ Laura ŠEDA Václav HOFERKOVÁ Eva CHIODIN G. KOŠŤÁLOVÁ Lenka MLADONICKÁ PAVLASOVÁ Gabriela FILIP Daniel FARIA ZENI Pedro OPPELT Jan PANOVSKÁ Anna PLEVOVÁ Karla POSPÍŠILOVÁ Šárka ŠIMKOVIČ M. VRBACKÝ F. LYSÁK Daniel FERNANDES SM. DAVIDS MS. MAIQUES-DIAZ A. CHARALAMPOPOULOU S. MARTIN-SUBERO I. BROWN JR. DOUBEK Michael FORCONI Francesco MAYER Jiří MRÁZ Marek

Year of publication 2023
Type Conference abstract
MU Faculty or unit

Central European Institute of Technology

Citation
Attached files
Description Genetic resistance mechanisms to BCR inhibitors in CLL have been extensively described, but it remains unclear whether non-genetic adaptation might exist in CLL cells allowing for lasting lymphocytosis or resistance. We focused on the possible role of the Akt pathway in adapting to BCR inhibitors since, in mouse models, PI3K-Akt activation is the only known factor that rescues the apoptosis induced by BCR deletion in mature B cells.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.